Semaglutide vs Exenatide

Exenatide was the first approved GLP-1 receptor agonist, built on a Gila monster peptide; semaglutide is a later analogue of human GLP-1 engineered for weekly or oral dosing.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Semaglutide

A long-acting GLP-1 receptor agonist, the reference molecule of the modern incretin era in both injectable and oral form.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

	Semaglutide	Exenatide
The key difference	Human GLP-1-based, weekly	Exendin-4-based, twice-daily or weekly
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Semaglutide is a GLP-1 analogue with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin, extending its half-life to about a week.	Exendin-4 shares about 53% homology with GLP-1 but resists DPP-4 degradation.
Status	Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa.	Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.
Reported safety signals	Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping.	Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.
A key study	Reviews the safety profile of semaglutide across subcutaneous and oral formulations. (Front Endocrinol (Lausanne) 2021, PMID 34305810)	Reviews exenatide’s pharmacology, pharmacokinetics, efficacy and adverse effects; derived from Gila monster saliva. (Am J Health Syst Pharm 2006, PMID 16484515)

Exenatide marks the start of the class; semaglutide its mature form with the larger outcome programme. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Semaglutide] Safety of Semaglutide — Front Endocrinol (Lausanne) 2021. PMID 34305810
[Semaglutide] A systematic review of the effect of semaglutide on lean mass: insights from clinical trials — Expert Opin Pharmacother 2024. PMID 38629387
[Semaglutide] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial — JAMA 2021. PMID 33755728
[Exenatide] Exenatide — Am J Health Syst Pharm 2006. PMID 16484515
[Exenatide] Exenatide. Amylin/Eli Lilly — Curr Opin Investig Drugs 2003. PMID 12808888
[Exenatide] Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system — Sci Transl Med 2024. PMID 38985854

FREQUENTLY ASKED

What is the difference between Semaglutide and Exenatide?

Exenatide was the first approved GLP-1 receptor agonist, built on a Gila monster peptide; semaglutide is a later analogue of human GLP-1 engineered for weekly or oral dosing.

What is the regulatory status of Semaglutide and Exenatide?

Semaglutide: Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa. Exenatide: Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.

What safety signals have been reported?

Semaglutide: Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping. Exenatide: Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.

Which studies is this comparison based on?

For Semaglutide: “Safety of Semaglutide” (PMID 34305810); “A systematic review of the effect of semaglutide on lean mass: insights from clinical trials” (PMID 38629387); “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial” (PMID 33755728). For Exenatide: “Exenatide” (PMID 16484515); “Exenatide. Amylin/Eli Lilly” (PMID 12808888); “Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system” (PMID 38985854).